Russell NH, Hills RK, Thomas A, Thomas I, Kjeldsen L, Dennis M, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. 2021;107:1518–27. https://doi.org/10.3324/haematol.2021.279010.
Google Scholar
Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the center for international blood and marrow transplant research registry. Transplant Cell Ther. 2024;30:917.e911–2. https://doi.org/10.1016/j.jtct.2024.06.021.
Google Scholar
Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4:3180–90. https://doi.org/10.1182/bloodadvances.2019001266.
Google Scholar
Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2:2095–103. https://doi.org/10.1182/bloodadvances.2018021980.
Google Scholar
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135:449–52. https://doi.org/10.1182/blood.2019003662.
Google Scholar
Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102:1601–5. https://doi.org/10.1182/blood-2003-02-0489.
Google Scholar
Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109:3108–14. https://doi.org/10.1182/blood-2006-09-046219.
Google Scholar
Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2009;15:844–50. https://doi.org/10.1016/j.bbmt.2009.03.017.
Google Scholar
Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008;26:5767–74. https://doi.org/10.1200/jco.2008.17.7279.
Google Scholar
Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124:1372–7. https://doi.org/10.1182/blood-2014-04-567164.
Google Scholar
Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016;173:96–104. https://doi.org/10.1111/bjh.13931.
Google Scholar
Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012;97:1882–9. https://doi.org/10.3324/haematol.2012.067140.
Google Scholar
Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018;103:522–30. https://doi.org/10.3324/haematol.2017.176859.
Google Scholar
Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, et al. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transpl. 2017;52:1003–9. https://doi.org/10.1038/bmt.2017.63.
Google Scholar
Rodriguez R, Palmer J, Nakamura R, Parker PM, Nademanee AP, Snyder DS, et al. Tacrolimus and sirolimus as GVHD prophylaxis for HLA-MRD allogeneic HCT conditioned with 3 regimens: toxicity and efficacy in 70 patients. Blood. 2006;108:2867–2867. https://doi.org/10.1182/blood.V108.11.2867.2867.
Google Scholar
Nakamura R, Palmer JM, O’Donnell MR, Stiller T, Thomas SH, Chao J, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leuk Res. 2012;36:1152–6. https://doi.org/10.1016/j.leukres.2012.04.022.
Google Scholar
Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F, et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transpl. 2010;16:281–6. https://doi.org/10.1016/j.bbmt.2009.09.020.
Google Scholar
Mei M, Tsai NC, Mokhtari S, Al Malki MM, Ali H, Salhotra A, et al. Long-term outcomes of allogeneic hematopoietic cell transplant with fludarabine and melphalan conditioning and tacrolimus/sirolimus as graft-versus-host disease prophylaxis in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2020;26:1425–32. https://doi.org/10.1016/j.bbmt.2020.04.015.
Google Scholar
Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, et al. Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus- and tacrolimus-based GVHD prophylaxis. Biol Blood Marrow Transpl. 2019;25:287–92. https://doi.org/10.1016/j.bbmt.2018.09.009.
Google Scholar
Salhotra A, Hui S, Yang D, Mokhtari S, Mei M, Al Malki MM, et al. Long-term outcomes of patients with acute myelogenous leukemia treated with myeloablative fractionated total body irradiation TBI-based conditioning with a tacrolimus- and sirolimus-based graft-versus-host disease prophylaxis regimen: 6-year follow-up from a single center. Biol Blood Marrow Transpl. 2020;26:292–9. https://doi.org/10.1016/j.bbmt.2019.09.017.
Google Scholar
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509. https://doi.org/10.1080/01621459.1999.10474144.
Google Scholar
Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, et al. Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:1828–35. https://doi.org/10.1016/j.bbmt.2018.04.029.
Google Scholar
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. https://doi.org/10.1056/NEJMoa2012971.
Google Scholar
Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121:1048–55. https://doi.org/10.1002/cncr.29163.
Google Scholar
Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2019;25:728–33. https://doi.org/10.1016/j.bbmt.2018.11.016.
Google Scholar
Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, et al. Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transplant Cell Ther. 2021;27:921.e921–910. https://doi.org/10.1016/j.jtct.2021.08.007.
Google Scholar
Stelljes M, Middeke JM, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024;11:e324–e335. https://doi.org/10.1016/S2352-3026(24)00065-6.
Google Scholar
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease–based definition of complete remission? J Clin Oncol. 2016;34:329–36. https://doi.org/10.1200/jco.2015.63.3826.
Google Scholar
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273–83. https://doi.org/10.1200/jco.19.03011.
Google Scholar
Jensen LG, Stiller T, Wong JYC, Palmer J, Stein A, Rosenthal J. Total marrow lymphoid irradiation/fludarabine/ melphalan conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2018;24:301–7. https://doi.org/10.1016/j.bbmt.2017.09.019.
Google Scholar
Salhotra A, Bejanyan N, Yang D, Mokhtari S, Al Malki MM, Sandhu KS, et al. Multicenter pilot clinical trial of enasidenib as maintenance therapy after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) carrying IDH2 mutations. Blood. 2022;140:1890–2. https://doi.org/10.1182/blood-2022-169964.
Google Scholar
Artz A, Logan BR, Saber W, Geller N, Bellach A, Kou J, et al. The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: a prospective BMT-CTN study 1704. Blood. 2023;142:109–109. https://doi.org/10.1182/blood-2023-173855.
Google Scholar
Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015;21:2020–8. https://doi.org/10.1158/1078-0432.Ccr-14-0586.
Google Scholar
Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105:2527–34. https://doi.org/10.1182/blood-2004-06-2494.
Google Scholar
Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transpl. 2012;18:1727–33. https://doi.org/10.1016/j.bbmt.2012.06.014.
Google Scholar
Khaled SK, Palmer J, Stiller T, Senitzer D, Maegawa R, Rodriguez R, et al. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Bone Marrow Transpl. 2013;48:278–83. https://doi.org/10.1038/bmt.2012.175.
Google Scholar
Ali H, Yang D, Mokhtari S, Synold T, Amanam I, Artz AS, et al. Phase IIa study of adding itacitinib to tacrolimus/sirolimus Gvhd prophylaxis after fludarabine/melphalan-based Conditioning hematopoietic cell transplantation for acute leukemias, myelodysplastic syndrome, or myelofibrosis. Blood. 2022;140:1872–4. https://doi.org/10.1182/blood-2022-170323.
Google Scholar
Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, et al. In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018;103:531–9. https://doi.org/10.3324/haematol.2017.171199.
Google Scholar
Holtan SG, Hamadani M, WU J, AL Malki MM, Runaas L, Elmariah H, et al. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703. Blood. 2022;140:LBA-4–LBA-4. https://doi.org/10.1182/blood-2022-171463.
Google Scholar
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48. https://doi.org/10.1056/NEJMoa2215943.
Google Scholar
Kean L, Siegel SJ, Schmalz JT, Bien SA, Scheffey D, Sanders C, et al. Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study. Blood. 2023;142:475–475. https://doi.org/10.1182/blood-2023-188032.
Google Scholar
Gooptu M, Romee R, St. Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82. https://doi.org/10.1182/blood.2021011281.
Google Scholar
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44. https://doi.org/10.1056/NEJMoa1706640.
Google Scholar
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10. https://doi.org/10.1056/NEJMoa1917635.
Google Scholar
